VARMX
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
VARMX
Social Links:
Industry:
Manufacturing Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.varmx.com
Total Employee:
1+
Status:
Active
Contact:
31 71 5156127
Email Addresses:
[email protected]
Total Funding:
109.58 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics LetsEncrypt
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Altamira Therapeutics
Altamira Therapeutics develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
EQT Life Sciences
EQT Life Sciences investment in Series B - VarmX
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series B - VarmX
BioGeneration Ventures
BioGeneration Ventures investment in Series B - VarmX
European Innovation Council
European Innovation Council investment in Series B - VarmX
LEH
LEH investment in Series B - VarmX
Wake Forest Innovation Quarter
Wake Forest Innovation Quarter investment in Series B - VarmX
Sound Bioventures
Sound Bioventures investment in Series B - VarmX
Ysios Capital
Ysios Capital investment in Series B - VarmX
European Innovation Council
European Innovation Council investment in Grant - VarmX
European Innovation Council
European Innovation Council investment in Venture Round - VarmX
Key Employee Changes
| Date | New article |
|---|---|
| 2023-10-12 | VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility |
Official Site Inspections
http://www.varmx.com Semrush global rank: 5.43 M Semrush visits lastest month: 1.38 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VarmX"
VarmX
Nov 14, 2024 · VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces... Our team is always available to answer …See details»
About VarmX
We are proud to have the backing of a strong syndicate of investors, including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and …See details»
Our team - VarmX
Management appointments in Large and Mid-Cap US/EU Biopharma companies (Novo Nordisk, ZymoGenetics inc). Proven track record with product approvals, financing, M&A and IPO at Nasdaq (ZGEN) and Euronext (ONWD.BR).See details»
VarmX - Crunchbase Company Profile & Funding
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients.See details»
VarmX Company Profile 2024: Valuation, Funding
Where is VarmX headquartered? VarmX is headquartered in Leiden, Netherlands. What is the size of VarmX? VarmX has 22 total employees. What industry is VarmX in? VarmX’s primary industry is Drug Discovery. Is VarmX a …See details»
VarmX - EQT Group
Nov 18, 2024 · Dutch biotech company developing an innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants.See details»
VarmX BV - European Commission - European …
The first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants. VarmX is a biotech company focusing on the development of innovative approaches for …See details»
VarmX - The Lundbeck Foundation
VarmX is a drug development company, developing drugs to restore haemostasis in case of bleeding or emergency surgery in patients taking oral factor Xa inhibitors.See details»
VarmX
Sep 10, 2024 · VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has appointed experienced life sciences industry executive, …See details»
VarmX - Sound Bioventures
VarmX is a clinical stage company developing drugs that reverse the action of direct acting oral anticoagulants (DOACs).The lead program is a recombinant protein, VMX-C001, that addresses the need of a safe and more efficacious …See details»
VarmX Company Profile - Office Locations, Competitors, Revenue …
VarmX is a company that manufactures therapeutic proteins to instantaneously restore blood clotting in bleeding patients. It is focused on the development of therapies in the field of …See details»
VarmX Raises € 12.5 Million to Develop Modified Blood ... - BioSpace
Jul 2, 2018 · VarmX is developing lead compound PseudoXa to stop or prevent bleeding in patients taking anti-coagulants in the form of synthetic factor Xa inhibitors. The product is …See details»
VarmX to present new data at the ISTH Congress - PharmaTimes
Jul 8, 2022 · VarmX – which focuses on the development of innovative approaches for the reversal of anticoagulation – has announced it will present new preclinical data on the …See details»
VarmX
VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, …See details»
First Subjects Dosed in First-in-Human Trial for VarmX’s …
Dec 15, 2021 · VarmX is a clinical-stage pharmaceutical company founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis, as a spin-off from the …See details»
VarmX Announces Appointment of John Glasspool as CEO
Nov 12, 2024 · VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation …See details»
VarmX raises €30M for blood clotting trial - labiotech.eu
May 26, 2023 · VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has successfully raised an additional €30 million ($32.2 …See details»
VarmX
Dec 15, 2021 · VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of the first subjects …See details»
VarmX raises funds to obtain IND approval for VMX-C001
Biotechnology company VarmX has raised an additional €30m in a Series B2 financing round to obtain investigational new drug (IND) approval for its lead compound VMX-C001. VMX-C001 …See details»
Our portfolio - VarmX
The VarmX pipeline program aims to broaden the utility of recombinant factor X as therapeutic protein. Two factor X candidate molecules have progressed to lead candidate phase. One …See details»